Michael G. Natchus

This study identifies EIDD-3525 as a broad-spectrum antiviral against alphaviruses that inhibits RNA replication by targeting the nsP4 polymerase.

This paper develops a new antiviral compound, GHP-88310, showing high tolerability and oral efficacy against measles and respiratory paramyxoviruses in animal models.

This study evaluates late-onset antiviral treatment in immunocompromised mice with persistent SARS-CoV-2 infection, finding that 4-FlU significantly reduces virus load, while paxlovid causes viral rebound.

This study shows that prior respiratory virus infections worsen measles severity in ferrets and that antiviral treatment can mitigate immune amnesia and disease outcomes regardless of treatment timing.

This study identifies mutations conferring resistance to 4-fluorouridine in influenza viruses and shows that resistant variants are attenuated in vivo and can be overcome by higher drug doses.